Subscribe to RSS
DOI: 10.1055/s-2002-35553
Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD)
Guidelines for the Diagnosis and Treatmental Chronic Obstructive Bronchitits and Pulmonary Emphysema Issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für PneumologiePublication History
Publication Date:
20 November 2002 (online)
![](https://www.thieme-connect.de/media/pneumologie/200211/lookinside/thumbnails/10.1055-s-2002-35553-1.jpg)
Inhalt Seite Vorwort 705 Ziele und Anwendungsbereich der Leitlinie 705 Entwicklungsprozess der Leitlinie 705 Sponsoring 706 Strategien zur Förderung der Verbreitung und Implementierung der Leitlinie 706 Weiterentwicklung der COPD-Leitlinie 707 Definitionen 707 Epidemiologie und sozialökonomische Bedeutung 707 Verlauf der Erkrankung 708 Management der COPD 708 Diagnostik 708 Untersuchungsmethoden 708 Diagnostisches Vorgehen bei Verdacht auf COPD 711 Schweregradeinteilung 712 Differenzialdiagnose 713 Verlaufsuntersuchungen 713 Therapie 714 Prävention 714 - Raucherentwöhnung 714 - Schutzimpfungen 715 Langzeitbehandlung der stabilen COPD 715 - Bronchodilatatoren 716 - Glukokortikoide 718 - Mukopharmaka 719 - Immunmodulatoren 719 - Antitussiva 719 - Atemstimulanzien 719 - Analgetika 719 - Substitutionstherapie bei Alpha-1-Proteinase-Inhibitor-Mangel 719 - Behandlung der Osteoporose 720 Nichtmedikamentöse Therapie 720 - Ernährung 720 - Patientenschulung 720 - Physiotherapie 721 - Pneumologische Rehabilitation 721 - Langzeitbehandlung mit O2 723 - Heimbeatmung 723 - Operative Therapieverfahren 724 Management der akuten Exazerbation 725 - Diagnostik 726 - Therapie der Exazerbation 726 - Betreuung des Patienten nach akuter Exazerbation 730 - Exazerbationsprophylaxe 730 Gemeinsamkeiten und Unterschiede der Leitlinie im Vergleich zur GOLD-Leitlinie 730 Appendix A: Berufsbedingte Bronchitis - Arbeitsmedizinische Aspekte der chronischen Bronchitis 731 Appendix B: Teilnehmerliste der Konsensus-Konferenz 732 Literaturverzeichnis 733
Literatur
- 1 Wettengel R, Böhning W, Cegla U. et al . Empfehlungen der Deutschen Atemwegsliga zur Behandlung von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem. Med Klin. 1995; 90 3-7
- 2 Pauwels R A, Buist A S, Calverley P MA. et al . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 163 1256-1276
- 3 ATS Statement . Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995; 152 S77-S120
- 4 Siafakas N M, Vermeire P, Pride N B. et al . ERS-Consensus statement. Optimal assessment and management of chronic obstructive pulmonary disease. Eur Respir J. 1995; 8 1388-1420
- 5 BTS . Guidelines for the management of chronic obstructive pulmonary disease. Thorax. 1997; 52 (Suppl 5) S1-S28
- 6 Canadian Respiratory Review Panel .Guidelines for the treatment of chronic obstructive pulmonary disease (COPD). Monograph 1998
- 7 Laitinen L, Koskela K. et al . Chronic bronchitis and chronic obstructive pulmonary disease: Finnish national guidelines for prevention and treatment 1998 - 2007. Respir Med. 1999; 93 207-332
- 8 Lorenz W, Ollenschläger G. et al . Das Leitlinienmanual von AWMF und ÄZQ. ZaeFQ. 2001; 95 (Suppl. I) 41-43
- 9 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften .Erarbeitung von Leitlinien für Diagnostik und Therapie. Methodische Empfehlungen. Abrufbar unter: http://www.uni-duesseldorf.de/WWW/AWMF
- 10 Society for Medical Decision Making . Committee on standardization of clinical algorithms. Proposals for clinical algorithm standards. Med Decis Making. 1992; 12 149-154
- 11 Report of an expert committee . Definition and diagnosis of pulmonary disease with special reference to chronic bronchitis and emphysema. WHO Techn Rep Ser. 1961; 213 14-19
- 12 Ciba guest symposium report . Terminology, definitions and classifications of chronic pulmonary emphysema and related conditions. Thorax. 1959; 14 286-299
- 13 Konietzko N, Fabel H. Weißbuch Lunge 2000. Stuttgart-New York: Thieme
- 14 Statistisches Bundesamt .Statistisches Jahrbuch, Jahrgänge 1968 - 1999. Stuttgart-Mainz: Kohlhammer
- 15 Murray C JL, Lopez A D. The global burden of disease: A comprehensive assessment of mortality and disability from diseases. Injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press 1996
- 16 Lopez A D, Murray C JL. The global burden of disease, 1990 - 2020. Nature Med. 1998; 4 1241-1243
- 17 Rychlik R, Pfeil T, Daniel D. et al . Zur sozioökonomischen Relevanz akuter Exacerbationen der chronischen Bronchitis in der Bundesrepublik Deutschland. Dtsch Med Wschr. 2001; 126 353-359
- 18 Laurell C B, Eriksson S. The electrophoretic alpha-1 globulin pattern of serum in alpha-1 antitrypsin deficiency. Scand J Clin Lab Invest. 1963; 15 132-140
- 19 Orie N GM, Sluiter H J, De Vreis K. et al .The host factor in bronchitis. In: Orie NGM, Sluiter HJ, (eds). Bronchitis, an international symposium. Assen, Netherlands: Royal Vangorum 1961: 43-59
- 20 Svanes C, Omenaas E, Heuch J M. et al . Birth characteristics and asthma symptoms in young adults: results from a population-based cohort study in Norway. Eur Respir J. 1998; 12 1366-1370
- 21 Todisco T, de Benedictis F M, Iannacci L. et al . Mild prematurity and respiratory functions. Eur J Pediatr. 1993; 152 55-58
- 22 Stein C E, Kumaran K, Fall C H. et al . Relation of fetal growth to adult lung function in South India. Thorax. 1997; 52 895-899
- 23 Morgan W J. Maternal smoking and infant lung function: further evidence for an in utero effect. Am J Respir Crit Care Med. 1998; 158 689-690
- 24 U. S. Surgeon General .The health consequences of smoking: chronic obstructive pulmonary disease. Washington DC.: U. S. Department of health and human services 1984 Publication No. 84 - 50 205
- 25 Leuenberger P, Schwartz J, Ackermann-Liebrich U. et al . Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on air pollution and lung diseases in adults. SAPALDIA Team. Am J Respir Crit Care Med. 1994; 150 1222-1228
- 26 Dayal H H, Khuder S, Sharrar R. et al . Passive smoking in obstructive respiratory disease in an industrialized urban population. Environ Res. 1994; 65 161-171
- 27 Holt P G. Immune and inflammatory function in cigarette smokers. Thorax. 1987; 42 241-249
- 28 Kauffmann F, Droulet D, Lellouch J. et al . Twelve years spirometric changes among Paris area workers. Int J Epidemiol. 1979; 8 201-212
-
29 Niewoehner D E. Anatomic and pathophysiological correlations in COPD In Baum Gl, Crapo JD, Celli BR, Karlinsky JB, (eds.) Textbook of pulmonary diseases. Philadelphia: Lippincott-Raven 1998: 823-842
- 30 Chen J C, Mannino M D. Worldwide epidemiology of chronic obstructive pulmonary disease. Current Opin Pulmon Med. 1995; 5 93-99
- 31 Behera D, Jindal S K. Respiratory symptoms in Indian women using domestic cooking fuels. Chest. 1991; 100 385-388
- 32 Georgopoulos D, Anthonisen N R. Symptoms and signs of COPD. In: Cherniack NS (ed). Chronic obstructive pulmonary disease. Toronto: Saunders 1991: 357-363
- 33 Taube M D, Lehnigk B, Paasch K. et al . Factor analysis of changes in dyspnea and lung function parameters after bronchodilatation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000; 162 216-220
- 34 O'Donnell D E, Lam M, Webb K A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 158 1557-1565
- 35 O'Donnell D E, Lam M, Webb K A. Spirometric correlates for improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 160 542-549
- 36 Marin J M, Carrizo S J, Gascon M. et al . Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 163 1395-1399
- 37 Seemungal T A, Donaldson G C, Bhownik A. et al . Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000; 161 1608-1613
- 38 Traver G A, Cline M G, Burrows B. Predictors of mortality in COPD. Am Rev Respir Dis. 1979; 119 895-902
- 39 Burrows B. The course and prognosis of different types of chronic airflow limitation in a general population sample from Arizona: comparison with the Chicago “COPD” series. Am Rev Respir Dis. 1989; 140 92-94
- 40 Quanjer P H. Standardised lung function testing. Official statement of the European Respiratory Society. Eur Respir J. 1993; 6 (Suppl 16) 5-40
- 41 Tweeddale P W, Alexander F, McHardy G JR. Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax. 1987; 42 87-90
- 42 Guyatt G H, Townsend M, Nogradi S. et al . Acute response to bronchodilator. An imperfect guide for bronchodilator therapy in chronic airflow limitation. Arch Intern Med. 1988; 148 1949-1952
- 43 Berger R, Smith D. Effect of an inhaled metaproterenol on exercise performance in patients with stable “fixed” airway obstruction. Am Rev Respir Dis. 1988; 138 626-629
- 44 Gross N, Tashkin D, Miller R. et al . Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration. 1998; 65 354-362
- 45 Guyatt G H, Townsend M, Pugsley S O. et al . Bronchodilators in chronic air-flow limitation: effects on airway function, exercise capacity and quality of life. Am Rev Respir Dis. 1987; 135 1069-1074
- 46 Callahan C M, Cirrus R S, Katz B P. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med. 1991; 114 216-223
- 47 American Thoracic Society . Lung function testing: selection of reference values and interpretation strategies. Am Rev Respir Dis. 1991; 144 202-218
- 48 Roberts C M, Bugler J R, Melchor R. et al . Value of pulse oximetry for long-term oxygen therapy requirement. Eur Respir J. 1993; 6 559-562
- 49 Hughes J MB, Pride N B. In defense of the carbon monoxide transfer coefficent Kco(TL/VA). Eur Respir J. 2001; 17 168-174
- 50 McLean A, Warren P M, Gilooly M. et al . Microscopic and macroscopic measurement of emphysema: relation to carbon monoxide transfer. Thorax. 1992; 47 14-19
- 51 Gevenois P A, de Vuyst P, de Maertelaer V. et al . Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med. 1996; 154 187-192
- 52 Gould G A, Redpath A T, Ryan M. et al . Lung CT density correlates with measurements of airflow limitation and the diffusing capacity. Eur Respir J. 1991; 4 141-146
- 53 Worth H, Breuer H-W M, Dorow P. et al .Deutsche Gesellschaft für Pneumologie. Empfehlungen zur Durchführung und Bewertung von Belastungsuntersuchungen in der Pneumologie. 52 1998: 225-231
- 54 Thurlbeck W M, Simon G. Radiographic appearance of the chest in emphysemas. Am J Roentgenol. 1978; 130 429-440
- 55 Morgan M DL, Denison D M, Stricklund B. Value of computed tomography for selecting patients with bullous emphysema. Thorax. 1986; 41 855-862
- 56 Lehtonen J, Sutinen S, Ikaheimo M. et al . Electrocardiographic criteria for the diagnosis of right ventricular hypertrophy verified at autopsy. Chest. 1988; 93 839-842
- 57 Niedermeier J, Barner A, Borst M. et al . Deutsche Gesellschaft für Pneumologie. Empfehlungen zur Anwendung der Echokardiographie in der pneumologischen Diagnostik. Pneumologie. 1998; 52 519-521
- 58 Worth H, Adam D, Handrick W. et al . Prophylaxe und Therapie von bronchopulmonalen Infektionen. Empfehlungen der Deutschen Atemwegsliga. Pneumologie. 1998; 52 232-237
- 59 O'Donnell D E, Forkert L, Webb K A. Evaluation of bronchodilator responses in patients with “irreversible” emphysema. Eur Respir J. 2001; 18 914-920
- 60 Begin P, Grassino A. Inspiratory muscle dysfunction and chronic hypercapnia in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1991; 143 901-903
- 61 Baldi S, Miniati M, Bellina C R. et al . Relationship between extent of pulmonary emphysema by high-resolution computed tomography and lung elastic recoil in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 169 585-589
- 62 Wolkove N, Dacezman E, Colacone A. et al . The relationship between pulmonary function and dyspnoea in obstructive lung disease. Chest. 1989; 96 1247-1251
- 63 Connolly M C, Crowley J J, Charan N B. et al . Reduced subjective awareness of bronchoconstriction by metacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax. 1992; 47 410-413
- 64 Wilson D H, Wakefield M A, Steven I D. et al . “Sick of smoking” evaluation of a targeted minimal smoking cessation intervention in general practice. Med J Aust. 1990; 152 518-521
- 65 Britton J, Knox A. Helping people to stop smoking: the new smoking cessation guidelines. Thorax. 1999; 54 1-2
- 66 Kottke T E, Ballista R N, de Friese G H. et al . Attributes of successful smoking cessation interventions in medical practise. A meta-analysis of 39 controlled trials. JAMA. 1988; 259 2883-2889
- 67 Ockene J K, Kristeller J, Goldberg R. et al . Increasing the efficacy of physician delivered smoking interventions: a randomized controlled clinical trial. J Gen Intern Med. 1991; 6 1-9
- 68 Fiore M C, Bailey W C, Cohen S J. Smoking cessation: information for specialists. U.S. department of health and human services. Public health service. Agency for health care policy and research and centers for disease control and prevention. Rockville: M.D. AHCPR 1996 Publication No. 96 - 0694
- 69 The tobacco use and dependence clinical practice guideline panel, staff and consortium repesentatives . A clinical practice guideline for treating tobacco use and dependence. JAMA. 2000; 83 3244-3254
- 70 American Medical Association .Guidelines for the diagnosis and treatment of nicotine dependence. How to help patients stop smoking. Washington D.C.: American Medical Association 1994
- 71 Glynn T J, Manley M W. How to help your patients stop smoking. A national cancer institute manual for physicians. Bethesda M.D. U.S. Department of health and human service, public health service. National institutes of health. National Cancer Institute NIH Publication 90 - 3064 1990
- 72 Anthonisen N R, Connett J E, Kiley J P. et al . Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study. JAMA. 1994; 272 1497-1505
- 73 Arzneimittelkommission der Deutschen Ärzteschaft .Empfehlungen zur Therapie der Tabakabhängigkeit. Köln: AVP-Reihe 2001
- 74 Jorenby R E, Leischow S J, Nides M A. et al . A controlled trial of sustained release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999; 340 685-691
- 75 Tashkin D P, Kanner R J, Buist S. et al . Smoking cessation in patients with chronic obstructive pulmonary disease: a double blind, placebo-controlled randomised trial. Lancet. 2001; 357 1571-1575
- 76 WHO .Tobacco free initiative: Policies for public Health. www.who//int/toh/world nottobacco 99
- 77 Fiore M C, Bailey W C, Cohen S J. et al .Treating tobacco use as dispendence: A clinical practical guideline. A public health service report. Rockville, M.D.: US Dept Health and Human Services 2000
- 78 Schwartz J L. Review and evalution of smoking cessation methods: United States and Canada, 1978 - 1985. Bethesda, M.D.: National Institute of Health 1987 NIH publication 87 - 2940
- 79 Fiore M C, Smith S S, Jorenby D E. et al . The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA. 1994; 271 1940-1947
- 80 Sachs D E, Benowitz N L. Individual medical treatment for tobacco dependence [editorial; comment]. Eur Respir J. 1996; 9 629-631
- 81 Nichol K, Margolis L, Wourenma J. et al . The efficacy and cost effectiveness of vaccination against influenza among elderley persons living in the community. N Engl J Med. 1994; 331 778-784
- 82 Hak E, van Essen G A, Buskens E. et al . Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general based clinical prospective cohort study in Utrecht. The Netherlands. J Epidemiol Community Health. 1998; 52 120-125
- 83 Simberkoff M S, Cross A P, Al-Ibrahim M. et al . Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986; 315 1318-1327
- 84 Williams J HJ, Moser K M. Pneumococcal vaccine and patients with chronic lung disease. Ann Intern Med. 1986; 104 106-109
- 85 Christenson B, Lundbergh P, Hedlund J. et al . Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet. 2001; 357 1008-1011
- 86 Davis A L, Aranda P, Schiffman G. et al . Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest. 1994; 92 204-212
- 87 Schaberg T. Pneumokokkenschutzimpfung. Pneumologie. 2001; 55 543-545
- 88 Ständige Impfkommission am Robert Koch-Institut (STIKO) .Epidemiologisches Bulletin des RKI. 28 2001: 203-218
- 89 Pauwels R A, Lofdahl C G, Laitinen L A. et al . Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med. 1999; 340 1948-1953
- 90 Vestbo J, Sorensen T, Langer P. et al . Longterm effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999; 355 1819-1823
- 91 Burge P S, Calverley M A, Jones P W. et al . Randomised, placebo-controlled study of fluticasone proprionate in patients with moderate to severe chronic obstructive pulmonary disease; the Isolde trial. Br Med J. 2000; 320 1297-1303
- 92 The Lung Health Study Research Group . Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000; 343 1902-1909
- 93 Van Schayck C P, Dompeling E, van Heerwaarden C LA. et al . Bronchodilator treatment in modern asthma or chronic bronchitis. Continuous or on demand. A randomised controlled study. BMJ. 1991; 303 1426-1431
- 94 Voshaar T, App E M, Berdel D. et al . Empfehlungen für die Auswahl von Inhalationssystemen für die Medikamentenverabreichung. Pneumologie. 2001; 55 579-586
- 95 Nisar M, Earis J E, Pearson M G. et al . Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992; 146 555-559
- 96 Ulrik C S. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax. 1995; 50 750-754
- 97 Grove A, Lipworth B J, Reid P. et al . Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax. 1996; 51 689-693
- 98 Boyd G, Mirice A H, Pounsford J G. et al . An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1997; 10 815-821
- 99 Maesen B LP, Wedermann C JJ, Duarkens V AM. et al . Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. Eur Respir J. 1999; 13 1103-1108
- 100 Jones P W, Bosh T K. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997; 155 1283-1289
- 101 Cazzola M, Imperatore F, Salzillo A. et al . Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmia. Chest. 1998; 114 411-415
- 102 Karpel J P, Pesin J, Greenberg D. et al . A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exazerbations of COPD. Chest. 1990; 98 835-839
- 103 Patrick D M, Dales R E, Stark R M. et al . Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy. Chest. 1990; 98 295-297
- 104 Braun S R, Mc Kenzie W N, Copeland C. et al . A comparison of the effect of ipratropium and albuterol in the treatment of chronic airways disease. Arch Intern Med. 1989; 149 544-547
- 105 Tashkin D P, Ashutosh K, Bleeker E R. et al . Comparison of the anticholinergic bronchodilator ipratropiumbromide with metaproterenol in chronic obstructive pulmonary disease: a multicenter study. Am J Med. 1986; 81 (Suppl. 5a) 1411-1419
- 106 COMBIVENT Inhalation Aerosol Study Group . In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest. 1994; 105 1411-1419
- 107 Rennard S I. Extended bronchodilator treatment in chronich obstructive pulmonary disease. Eur Respir Rev. 1996; 6 282-286
- 108 Barnes P J. The pharmacological properties of tiotropium. Chest. 2000; 117 63-66
- 109 Calverley P MA. The future of tiotropium. Chest. 2000; 117 67-69
- 110 Casaburi R, Mahler D A, Jones P W. et al . A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002; 19 217-224
- 111 Vincken W, von Noord J A, Greefhorst A P. et al . Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002; 19 209-216
- 112 Murciano D, Auclair M-A, Pariente R. et al . A randomized controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Eng J Med. 1989; 320 1512-1525
- 113 Mc Kay S E, Howie C A, Thomson A H. et al . Value of theophylline treatment in patients handicapped by chronic obstructive pulmonary disease. Thorax. 1993; 48 227-232
- 114 Mulloy E, Mc Nicholas W T. Theophylline improves gas exchange during rest, exercise and sleep in severe chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993; 148 1030-1036
- 115 Evans W W. Plasma theophylline concentrations, six minute walking distances and breathlessness in patients with chronic airflow obstruction. BMJ. 1984; 289 1649-1651
- 116 Cooper C B, Davidson A C, Cameron I R. Aminophylline, respiratory muscle strength and exercise tolerance in chronic obstructive airway disease. Clin Respir Physiol. 1987; 23 15-22
- 117 Murciano D, Aubier M, Lecolguic Y. et al . The effects of theophylline on diaphragmatic strength an exercise tolerance in patients with chronic obstructive pulmonary disease. N Engl J Med. 1984; 322 349-353
- 118 Williamson B H, Milligan C, Griffiths K. et al . An assessment of major and minor side effects of theophylline. Aust NZ J Med. 1988; 19 539
- 119 Kirsten D, Wegner R E, Jörres R A. et al . Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest. 1993; 104 1101-1107
- 120 The COMBIVENT Inhalation Solution Study Group . Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest. 1997; 112 1514-1521
- 121 Taylor D R, Buick B, Kinney C. et al . The efficacy of orally administered theophylline, inhaled salbutamol and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible airflow obstruction. Am J Respir Dis. 1985; 131 747-751
- 122 Van Noord J A, de Munck D R, Bantje T A. et al . Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J. 2000; 15 878-885
- 123 D'Urzo A D, de Salvo M C, Ramirez-Rivera A. et al . In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. Chest. 2001; 119 1347-1356
- 124 O'Driscoll B R, Kay E A, Taylor R J. et al . A long-term prospective assessment of home nebulizer treatment. Respir Med. 1992; S6 317-325
- 125 Washkin D P, Bleecker E, Braun S. et al . Results of a multicenter study of nebulized inhalant bronchodilator solutions. Am J Med. 1996; 100 62-69
- 126 Senderovitz T, Vestbo J, Frandsen J. et al . Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society or Respiratory Medicine. Respir Med. 1999; 93 715-718
- 127 Rice K L, Rubins J B, Lebhahn F. et al . Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am J Respir Crit Care Med. 2000; 162 174-178
- 128 Decramer M, Lacquet L M, Fagard R. et al . Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994; 150 11-16
- 129 Decramer M, Stas K J. Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am J Respir Dis. 1992; 146 800-802
- 130 Schols A MWJ, Wesseling G, Keser A DM. et al . Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J. 2001; 17 337-342
- 131 Grassi C. and the multicenter Study Group . Longterm oral acetylcysteine in chronic bronchitis. A double blind controlled study. Eur J Respir Dis. 1980; 61 (Suppl. 111) 93-108
- 132 Boman G, Bäcker U, Larsson S. et al . Oral acetylcysteine reduces exacerbation rate in chronic bronchitis. Report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis. 1983; 64 405-415
- 133 Jackson M, Barnes J, Cooksey P. Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: A double-blind placebo-controlled study. J Int Med Res. 1984; 12 198-205
- 134 Mc Gavin C R. and the British Thoracic Society Research Committee . Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airway obstruction. Thorax. 1985; 40 832-835
- 135 Meister R. Langzeittherapie mit Acetylcystein Retard-Tabletten bei Patienten mit chronischer Bronchitis. Eine doppelblinde-placebokontrollierte Studie. Forum Prakt Allg Arzt. 1986; 25 18-22
- 136 Parr G D, Huitson A. Oral fabrol (oral N-acetylcysteine) in chronic bronchitis. Br J Dis Chest. 1987; 81 341-348
- 137 Rasmussen J B, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J. 1988; 1 351-355
- 138 Hansen N CG, Skriver A, Brorsen-Ries L. et al . Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med. 1994; 88 531-535
- 139 Pela R, Calcagni A M, Subiaco S. et al . N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration. 1999; 66 495-500
- 140 Grandjean E M, Berthet P, Ruffmann R. et al . Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A metaanalysis of published double blind, placebo-controlled clinical trials. Clin Therapeutics. 2000; 22 209-221
- 141 Stey C, Steuer J, Bachmann S. et al . The effect of oral N-acetylcysteine in chronic bronchitis - a quantitative systematic review. Eur Respir J. 1999; 14 (Suppl. 30) 381S
- 142 Poole P J, Black P N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease. BMJ. 2001; 322 1-6
- 143 Olivieri D, Zavattini G, Tomasini G. et al . Ambroxol for the prevention of chronic bronchitis exazerbations: long term multicenter trial. Respiration. 1987; 51 (Suppl 1) 42-51
- 144 Collet J P, Shapiro S, Ernst P. et al . Effect of an immunostimulating agent on acute exacerbations and hospitalizations in COPD patients. Am J Respir Crit Care Med. 1997; 156 1719-1724
- 145 Anthonisen N R. Editoral. OM-85BV for COPD. Am J Respir Crit Care Med. 1997; 156 1713-1714
- 146 Irwin R S, Boulet L P, Cloutier M M. et al . Managing cough as a defense mechanism and as a symptom: a consensus panel report of the American College of Chest Physicans. Chest. 1998; 114 133S-181S
- 147 Bardsley P A, Howard P, DeBacker W. et al . Two years treatment with almitrine bismesylate in patients with hypoxic chronic obstructive airways disease. Eur Respir J. 1991; 4 308-310
- 148 Watanabe S, Kanner R E, Cutillo A G. et al . Long-term effect of almitrine bismesylate in patients with hypoxemic chronic obstructive pulmonary disease. Am J Respir Dis. 1989; 140 1269-1273
- 149 Winkelmann B R, Kullmer T H, Kneissl D G. et al .Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. Chest 105: 1383-1391
- 150 Eiser N, Denman W T, West C. et al . Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the “pink puffer” syndrome. Eur Respir J. 1991; 4 926-931
- 151 Young I H, Daviskas E, Keena V A. Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax. 1989; 44 387-390
- 152 Rice K L, Kronenberg R S, Hedemark L L. et al . Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Br J Dis Chest. 1987; 81 287-292
- 153 Woodcock A A, Gross E R, Gellert A A. et al . Effects of dihydrocodeine, alcohol and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med. 1981; 305 1611-1616
- 154 Poole P J, Veale A G, Black P N. The effect of sustained release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157 1877-1880
- 155 Schönhofer B, Suchi S, Haidl P. et al . Eine Epidemiologie zum Stellenwert von oral appliziertem Morphium als Therapieform des schwergradigen Lungenemphysems vom Pink-Puffer-Typ. Med Klin. 2001; 96 325-330
- 156 Alpha-1-Antitrypsin Deficiency Registry Group . Survival and FEV1 decline in individuals with severe deficiency of a1-antitrypsin. Am J Respir Crit Care Med. 1998; 158 49-59
- 157 Seersholm N, Kokjensen A. Clinical features and prognosis of life time non-smokers with severe α1-antitrypsin deficiency. Thorax. 1998; 53 265-268
- 158 Wencker M, Banik N, Buhl R. Long-term treatment of α1-antitrypsin deficiency related pulmonary emphysema with human α1-antitrypsin. Eur Respir J. 1998; 11 428-433
- 159 Incalci R A, Caradonna P, Ranieri P. et al . Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir Med. 2000; 94 1079-1084
- 160 American College of Rheumatology ad hoc Committee on glucocorticoid-induced osteoporosis . Recommendations for the prevention and treatment of glucocortocoid-induced osteoporosis. Arthritis Rheumatism. 2001; 44 1496-1503
- 161 Engelken M PKJ, Schols A MWJ, Baker W C. et al . Nutritional depletion in relation to respiratory and peripheral muscle function in outpatients with COPD. Eur Respir J. 1994; 7 1793-1797
- 162 Schols A MWJ, Soeters P B, Dingemans A MC. et al . Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993; 147 1187-1196
- 163 Wilson D O, Rogers R M, Wright E C. et al . Body weight in chronic obstructive pulmonary disease. The National Institutes of Health intermittend positive-pressure breathing trial. Am Rev Respir Dis. 1989; 139 1435-1438
- 164 Wouters E FM, Schols A MWJ. Nutritional depletion in COPD. Eur Respir Rev. 1997; 7 60-65
- 165 Fitting J W. Nutritional support in chronic obstructive lung disease. Thorax. 1992; 47 141-143
- 166 Hunter A BN, Carey M A, Lorch H W. The nutritional status of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985; 132 1347-1365
- 167 Gray-Donald K, Gibbone L, Shapiro S H. et al . Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996; 153 961-966
- 168 Baarends E M, Schols A MWJ, Mostert R. et al . Peak exercise in relation to tissue depletion in patients with chronic obstructive pulmonary disease. Eur Respir J. 1997; 10 2807-2813
- 169 Shoup R, Dalshy G, Warner G. et al . Body composition and health related quality of life in patients with chronic obstructive airways disease. Eur Respir J. 1997; 10 1576-1580
- 170 Schols A MWJ, Slangen J, Volorris A. et al . Weigth loss is a reversible factor in the prognosis of COPD. Am J Respir Crit Care Med. 1998; 157 1791-1797
- 171 Efthimiou J, Fleming J, Gomes C. et al . The effect of supplementary oral nutrition in poorly nourished patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1988; 137 1075-1082
- 172 Rogers R M, Donahue M, Constantino J. Physiologic effects of oral supplemental feeding in malnourished patients with chronic obstructive pulmonary disease patients. Am Rev Respir Dis 145: 1511-1597
- 173 Whittaker J S, Buckley C F, Road J D. The effects of re-feeding on peripheral and respiratory muscle function in malnourished chronic obstructive pulmonary disease patients. Am Rev Respir Dis. 1990; 142 283-288
- 174 Ries A L, Kaplan R M, Limberg T M. et al . Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med. 1995; 122 823-832
- 175 Toshima M C, Kaplan R M, Ries A L. Experimental evaluation of rehabilitation in chronic obstructive pulmonary disease. Short term effects on exercise endurance and health status. H Psychol. 1999; 9 237-252
- 176 Gallefoss F, Bakke P S. How does patient education and self management among asthmatics and patients with chronic obstructive pulmonary disease affect medication?. Am J Respir Crit Care Med. 1999; 160 2000-2005
- 177 Lacasse Y, Guyatt G H, Goldstein R S. The components of a rehabilitation program. A systematic review. Chest. 1997; 111 1077-1088
- 178 Dhein Y, Birkenmaier A, Otte B. et al . Evaluation of a structured education programme (AFBE) for patients with mild to moderate COPD under outpatient conditions. Am J Respir Crit Care Med. 2002; 165 A420
- 179 Murray J F. The ketch-up bottle method. N Engl J Med. 1979; 300 1155-1157
- 180 Anthonisen P, Ries P, Sogaard-Andersen T. The value of lung physiotherapy in the treatment of acute exacerbations in chronic bronchitis. Acta Med Scand. 1964; 145 715-719
- 181 Graham W, Bradley G A. Efficacy of chest physiotherapy and intermittent positive-pressure breathing in the resolution of pneumonia. N Eng J Med. 1978; 299 624-627
- 182 King M, Philips D M, Gron D. et al . Enhanced tracheal mucus clearance with high frequency chest wall percussion. Am Rev Respir Dis. 1983; 128 511-515
- 183 Pryer J A. Physiotherapy for airway clearance in adults. Eur Respir J. 1999; 14 1418-1424
- 184 Cegla U H, Petzow A. Physiotherapie mit dem VRP1 bei chronisch obstruktiven Atemwegserkrankungen - Ergebnisse einer multizentrischen Vergleichsstudie. Pneumologie. 1993; 47 636-639
- 185 App E M, Wunderlich M O, Lohse P. et al . Oszillierende Physiotherapie bei Bronchialerkrankungen - rheologischer und antientzündlicher Effekt. Pneumologie. 1999; 53 1-12
- 186 Cegla U H, Bautz M, Fröde G. et al . Physiotherapie bei Patienten mit COPD und tracheobronchialer Instabilität - Vergleich zweier oszillierender PEP-Systeme (RC-Cornet, VRP1-Destin). Pneumologie. 1997; 51 129-136
- 187 ACCP/AAC/VPR Pulmonary Rehabilitation Guidelines Panel . Pulmonary Rehabilitation. Chest. 1997; 112 1363-1395
- 188 American Thoracic Society . Pulmonary Rehabilitation. Am J Respir Crit Care Med. 1999; 159 1666-1682
- 189 Lacasse Y, Wong E, Guyatt G H. et al . Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet. 1996; 348 1115-1119
- 190 Hass A, Cardon H. Rehabilitation in chronic obstructive pulmonary disease: 5 year study of 252 patients. Med Clin North Am. 1969; 53 593-606
- 191 Sahn S A, Nett L M, Petty T L. Ten-year follow-up of a comprehensive rehabilitation programme for severe COPD. Chest. 1980; 77 311-314
- 192 Wedzicha J A, Bestall J C, Garrod R. et al . Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J. 1998; 12 363-369
- 193 Young P, Dewse M, Fergusson W. et al . Respiratory rehabilitation in chronic obstructive pulmonary disease: predictors of non-adherence. Eur Respir J. 1999; 13 867-872
- 194 Bergmann K, Fischer C J, Schmitz M. et al . Die stationäre Rehabilitation für Erwachsene. Zielsetzung - Diagnostik und therapeutische Standards - Forschungsbedarf. Pneumologie. 1997; 51 523-532
- 195 Szczepanski R, Taube K, Junggeburth J. et al . Ambulante wohnortnahe pneumologische Prävention und Rehabilitation bei obstruktiven Atemwegserkrankungen - Stand, Perspektive und Forschungsbedarf. Pneumologie. 1998; 52 476-482
- 196 Goldstein R S, Gort E H, Stubbing D. et al . Randomized controlled trial of respiratory rehabilitation. Lancet. 1994; 344 1394-1397
- 197 Wijkstra P J, van Atena R, Kraan J. et al . Quality of life in patients with chronic obstructive pulmonary disease improve after rehabilitation at home. Eur Respir J. 1994; 7 307-311
- 198 McGavin C R, Gapta S P, Lloyd E L. et al . Physical rehabilitation for the chronic bronchitis. Results of a controlled trial of exercises in the home. Thorax. 1977; 32 307-311
- 199 Griffiths T L, Burr M L, Campbell I A. et al . Results at 1 year of out-patient multidisciplinary pulmonary rehabilitation. Lancet. 2000; 355 362-368
- 200 Worth H, Meyer A, Folgering H. et al . Empfehlungen der Deutschen Atemwegsliga zum Sport und körperlichen Training bei Patienten mit obstruktiven Atemwegserkrankungen. Pneumologie. 2000; 54 61-67
- 201 Bernhard S, Whittom F, Leblanc P. et al . Aerobic and strength training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 159 896-901
- 202 Belman M J, Botnick W C, Nathan S D. et al . Ventilatory load characteristics during ventilatory muscle training. Am J Respir Crit Care Med. 1994; 149 925-929
- 203 Foglio K, Bianchi L, Bruletti G. et al . Long-term effectiveness of pulmonary rehabilitation in patients with chronic airways obstruction. Eur Respir J. 1999; 13 125-132
- 204 Young P, Dewse M, Ferguson W. et al . Improvements in outcomes for chronic obstructive pulmonary disease (COPD) attributable to a hospital-based respiratory rehabilitation programme. Aus NZ J Med. 1999; 29 59-65
- 205 Carter R, Blevins W, Stocks J. et al . Cost and quality issues related to the management of COPD. Sem Resp Med. 1999; 20 199-212
- 206 Magnussen H, Goeckenjan G, Köhler D. et al . Leitlinien zur Sauerstoff-Langzeit-Therapie. Pneumologie. 2001; 55 454-464
- 207 Report of the Medical Research Council Working Party . Long-term domiciliary oxygen in chronic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981; 1 681-685
- 208 Nocturnal oxygen therapy trial group . Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease. Ann Intern Med. 1980; 93 191-198
- 209 Weitzenblum E, Sautegeau A, Ehrhart M. et al . Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985; 131 493-498
- 210 Leach R M, Davidson A C, Chinn S. et al . Portable liquid oxygen and exercise ability in severe respiratory disability. Thorax. 1992; 47 78-789
- 211 Tarpy S P, Celli B R. Long-term oxygen therapy. N Engl J Med. 1995; 333 710-714
- 212 Pelletier Fleury N, Laone J L, Fleury B. et al . The cost of treating COPD patients with long-term oxygen therapy in a French population. Chest. 1996; 110 411-416
- 213 Heaney L G, McAllister D, MacMahon J. Cost minimisation analysis of provision of oxygen at home: are the drug tariff guidelines cost effective?. BMJ. 1999; 319 19-23
- 214 Donahoe M, Rogers R M. Nutritional assessment and support in chronic pulmonary disease. Clin Chest Med. 1990; 11 487-504
- 215 Köhler D, Criée C-P, Raschke F. Leitlinien zur häuslichen Sauerstoff- und Heimbeatmungstherapie. Pneumologie. 1996; 50 927-931
- 216 Simmonds A K, Elliot M W. Outcome of domiciliary nasal intermittent positive pressure ventilation in restrictive and obstructive disorders. Thorax. 1995; 50 604-609
- 217 Meecham Jones D J, Paul E A, Jones P W. et al . Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med. 1995; 152 538-544
- 218 Consensus Conference . Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation. A consensus conference report. Chest. 1999; 116 521-534
- 219 Mehran R J, Deslauriers J. Indications for surgery and patient work-up for bullectomie. Chest Surg Clin N Am. 1995; 5 717-734
- 220 Hughes J A, Hutchison D M, MacArthur D CS. et al . Long-term changes in lung function after surgical treatment of bullos emphysema in smokers and exsmokers. Thorax. 1986; 39 140
- 221 Brantigan O C, Kress M B, Müller E A. A surgical approach to pulmonary emphysema. Dis Chest. 1961; 39 485-501
- 222 Cooper J D, Trulock E P, Triantafillou A N. et al . Bilateral pneumonectomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg. 1995; 109 106-119
- 223 Geddes D, Davies M, Koyama H. et al . Effect of lung volume reduction surgery in patients with severe emphysema. N Engl J Med. 2000; 343 239-245
- 224 Benditt J O, Albert R K. Surgical options for patients with advanced emphysema. Clin Chest Med. 1997; 18 577-593
- 225 A National Emphysema Treatment Trial Research Group . Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med. 2001; 345 1075-1083
- 226 Cassina P C, Teschler H, Konietzko N. et al . Two-year results after lung volume reduction surgery in alpha-1-antitrypsin deficiency versus smoker's emphysema. Eur Respir J. 1998; 12 1028-1032
- 227 Thurnheer R, Engel H, Weder W. et al . Role of lung perfusion scintigraphy in relation to chest computed tomography and pulmonary function in the evaluation of candidates for lung volume reduction surgery. Am J Respir Crit Care Med. 1999; 159 301-310
- 228 Brenner M, McKenna R JJ, Gelb A F. et al . Rate of FEV1 change following lung volume reduction surgery. Chest. 1998; 113 652-659
- 229 McKenna R J, Brenner M, Fischel R J. et al . Should lung volume reduction for emphysema be unilateral or bilateral?. J Thorac Cardivasc Surg. 1996; 112 1331-1339
- 230 Sciurba F C. Early and long-term functional outcomes following lung volume reduction surgery. Clin Chest Med. 1997; 18 259-276
- 231 Stamatis G, Teschler H, Fechner S. et al . Bilaterale Lungenvolumenreduktion bei Patienten mit schwerem Lungenemphysem. Pneumologie. 1996; 50 448-452
- 232 Wisser W, Deviatko E, Simon N. et al . Lung transplantation following lung volume reduction surgery. J Heart Lung Transplant. 2000; 19 480-487
- 233 Theodore J, Lewiston N. Lung transplantation comes of age. N Engl J Med. 1990; 322 772-774
- 234 Trulock E P. Lung transplantation. Am J Respir Crit Care Med. 1997; 155 789-818
- 235 Division of transplantation Bo .1995 Annual report of the US scientific registry for transplant recipients and the organ procurement and transplantation network. Transplant data: 1988 - 1994. Health Resources and Services Administration. US Department of Health and Human services 1995
- 236 Hosenpud J D, Novick R J, Bennett L E. et al . The registry of the international society for heart and lung transplantation: twelfth official report. J Heart Lung Transplant. 1996; 15 655-674
- 237 Hosenpud J D, Bennett L E, Keck B M. et al . Effects of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet. 1998; 3 24-27
- 238 Niedermeier J, Bewig B, Bickhardt T. et al . Lungen- und Herz- und Lungentransplantation. Leitlinien zur Indikationsstellung und Präoperativen Diagnostik. Pneumologie. 2001; 55 396-400
- 239 Trulok E P. Lung transplantation for COPD. Chest. 1998; 113 269-276
- 240 Ramsey S D, Patrick D L, Albert R K. et al . The cost-effectiveness of lung transplantation: a pilot study. Chest. 1995; 108 1594-1601
- 241 Molken M P, van Doorslaer E K, Rutten F F. Economic appraisal of asthma and COPD care: a literature review 1980 - 1991. Soc Sci Med. 1992; 35 161-175
- 242 Kroshus T J, Bolmann III R M, Kshettry V R. Unilateral volume reduction after single-lung transplantation for emphysema. Ann Thorac Surg. 1996; 62 363-368
- 243 Anderson M B, Kriett J M, Kapelanski D P. et al . Volume reduction surgery in the native lung after single lung transplantation for emphysema. J Heart Lung Transplant. 1997; 16 752-757
- 244 Anthonisen N R, Manfreda J, Warren C P. et al . Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106 196-204
- 245 Regueiro C R, Hamel M B, Davis R B. et al . A comparison of generalist and pulmonologist care for patients hospitalized with severe chronic obstructive pulmonary disease: resource intensity, hospital costs and survival. Am J Med. 1998; 105 366-372
- 246 Gibson P G, Wlodarczyk J H, Wilson A J. et al . Severe exacerbations of chronic obstructive airways disease: health resource use in general practice and hospital. J Qual Clin Pract. 1998; 18 125-133
- 247 Mushlin A I, Black E A, Connolly C A. et al . The necessary length of hospital stay for chronic pulmonary disease. JAMA. 1991; 266 80-83
- 248 Connors A F, Dawson N V, Thomas C. et al . Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators. Am J Respir Crit Care Med. 1996; 154 959-967
- 249 Kong G K, Belman M J, Weingarten S. Reducing length of stay for patients hospitalized with exacerbation of COPD by using a practice guideline. Chest. 1997; 111 89-94
- 250 Fuso L, Incalzi R A, Pistelli R. et al . Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med. 1995; 98 272-277
- 251 Seneff M G, Wagner D P, Wagner R P. et al . Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995; 274 1852-1857
- 252 MacFarlane J T, Colville A, Macfarlane R M. et al . Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet. 1993; 341 511-514
- 253 Stockley R A, O'Brien C, Pye A. et al . Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000; 117 1638-1645
- 254 Seemungal T R, Harpen-Owen R, Bhownik A. et al . Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164 1618-1623
- 255 Anderson H R, Spix C, Medina S. et al . Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Eur Respir J. 1997; 10 1064-1071
- 256 Emerman C L, Connors A F, Lukens T W. et al . Relationship between arterial blood gases and spirometry in acute exacerbations of chronic obstructive pulmonary disease. Ann Emerg Med. 1989; 18 523-527
- 257 Emerman C L, Effron D, Lukens T W. Spirometric criteria for hospital admission of patients with acute exacerbation of COPD. Chest. 1991; 99 595-599
- 258 Emerman C L, Lukes T W, Effron D. Physician estimation of FEV1 in acute exacerbation of COPD. Chest. 1994; 105 1709-1712
- 259 Emerman C L, Cydulka R K. Use of peak expiratory flow rate in emergency department evaluation of acute exacerbation of chronic obstructive pulmonary disease [see comments]. Ann Emerg Med. 1996; 27 159-163
- 260 Rice K L, Leatherman J W, Duane P G. et al . Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial. Ann Intern Med. 1987; 107 305-309
- 261 Barbera J A, Reyes A, Roca J. et al . Effect of intravenously administered aminophylline on ventilation/perfusion inequality during recovery from exacerbations of chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992; 145 1328-1333
- 262 Mahon J L, Laupacis A, Hodder R V. et al . Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. Chest. 1999; 115 38-48
- 263 Loberes P, Ramis L, Montserrat J M. et al . Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J. 1988; 1 536-539
- 264 Emerman C L, Connors A F, Lukens T W. et al . Theophylline concentrations in patients with acute exacerbation of COPD [see comments]. Am J Emerg Med. 1990; 8 289-292
- 265 Eller J, Ede A, Schaberg T. et al . Infective exacerbations of chronic bronchitis. Chest. 1998; 113 1542-1548
- 266 Vogel F, Worth H, Adam D. et al . Rationale Therapie bakterieller Atemwegsinfektionen. Empfehlungen einer Expertengruppe der Paul-Ehrlich-Gesellschaft für Chemotherapie und der Deutschen Atemwegsliga. Chemother J. 2000; 9 3-23
- 267 Thompson W H, Nielson C P, Carvalho P. et al . Controlled trial of oral prednisolone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996; 154 407-412
- 268 Davies L, Angus R M, Calverley P M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999; 354 456-460
- 269 Niewoehner D E, Erbland M L, Deupree R H. et al . Effect of systemic glucocorticoids on exacxerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999; 340 1941-1947
- 270 Bach P B, Brown C, Gelfand S E. et al . Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med. 2001; 134 600-620
- 271 Rossi A, Gottfried S B, Zocci L. et al . Respiratory mechanics in mechanically ventilated patients with respiratory failure. J Appl Physiol. 1985; 58 1849-1858
- 272 Georgopoulos D, Rossi A, Moxham J. Ventilatory support in chronic obstructive pulmonary disease. Eur Respir Mon. 1998; 7 189-208
- 273 Bott J, Carroll M P, Conway J H. et al . Randomized controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet. 1993; 341 1555-1557
- 274 Brochard L, Mancebo J, Wysocki M. et al . Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1995; 33 817-822
- 275 Kramer N, Meyer T J, Meharg J. et al . Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med. 1995; 151 1799-1806
- 276 Barbé F, Togores B, Rubi M. et al . Noninvasive ventilatory support does not facilitate recovery from acute respiratory failure in chronic obstructive pulmonary disease. Eur Respir J. 1996; 9 1240-1245
- 277 Plant P K, Owen J L, Elliott M W. Early use of non-invasive ventilation (NIV) for acute exacerbations of COPD on general respiratory wards: a multicenter randomized controlled trial. Lancet. 2000; 355 1931-1935
- 278 Nava S, Ambrosino N, Clini E. et al . Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial. Ann Intern Med. 1998; 128 721-728
- 279 Stoller J K, Lange P A. Inpatient management of chronic obstructive pulmonary disease. Respir Care Clin N Am. 1998; 4 425-438
- 280 Peach H, Pathy M S. Follow-up study of disability among elderly patients discharged from hospital with exacerbations of chronic bronchitis. Thorax. 1981; 36 585-589
- 281 Friedman M, Serby C W, Menjoge S S. et al . Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest. 1999; 115 635-641
- 282 Mahler D A, Donohue J F, Barbee R A. et al . Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999; 115 957-965
- 283 Morgan W KG, Reger R B. Chronic airflow limitation and occupation. In: Cherniack NS (Hrsg.): Chronic obstructive pulmonary disease Philadelphia: Saunders 1991
- 284 Nowak D. Berufsbedingte obstruktive Atemwegserkrankung (BK4301 und 4302) gutachterliche Anmerkungen zum Krankheitsbegriff und zur MdE. Arbeitsmed Sozialmed Umweltmed. 2000; 35 164-167
- 285 Morfeld P, Piekarski C. Chronische Bronchitis und Emphysem als Berufskrankheit der Steinkohlenbergleute. Schriftenreihe Zentralblatt für Arbeitsmedizin, Haefer 1998
- 286 Nowak D. Informationen zur neuen Berufskrankheit 4111: „Chronische obstruktive Bronchitis oder Emphysem von Bergleuten unter Tage im Steinkohlenbergbau bei Nachweis der Einwirkung einer kumulativen Feinstaubdosis von in der Regel 100 [(mg/m3) × Jahre]”. Pneumologie 1996: 652-654
- 287 Kroidl R F, Nowak D, Seysen U. Bewertung und Begutachtung in der Pneumologie. Thieme 1999
- 288 Bundesministerium für Arbeit und Sozialordnung .Anhaltspunkte für die ärztliche Gutachtertätigkeit im sozialen Entschädigungsrecht und nach dem Schwerbehindertengesetz. Köllen,. 1996
Prof. Dr. med. H. Worth
Medizinische Klinik I · Klinikum Fürth
Jakob-Henle-Str. 1
90766 Fürth
Email: med1@klinikum-fuerth.de